2001•GastroenterologyRequires access

The key to successful eradication of H. pylori, using lansoprazole or rabeprazole based triple therapy, is clarithromycin resistance, not CYP2C19 polymorphism

Ikuya Miki, Nobuo Aoyama, Toshiyuki Sakai, Daisuke Shirasaka, Shigeyuki Ebara, Casmir Wambura, Yoshihori Watanabe, Masaaki Kachi, Takao Tamura, Masaki Miyamoto, Masato Kasuga

Open publisher page 3 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Rabeprazole, Lansoprazole, CYP2C19, Clarithromycin, Helicobacter pylori, Gastroenterology, Medicine, Internal medicine

Back to paper search Browse research topics Original source

The key to successful eradication of H. pylori, using lansoprazole or rabeprazole based triple therapy, is clarithromycin resistance, not CYP2C19 polymorphism — Research Paper | ScholarLens